华安中证全指医疗器械指数发起式A（021469）基金经理为苏卿云。 截至发稿，苏卿云累计任职时间9年70天，现任基金资产总规模100.51亿元，任职期间最佳基金回报 131%， 任职期间最差基金回报-62.44%。 2月24日，英科医疗涨5.08%，截至发稿，报41.35元/股，成交1.74亿元，换手率0.93%，总市值270.91亿 元。 资料显示，英科医疗科技股份有限公司位于山东省淄博市临淄区齐鲁化学工业园清田路18号,香港湾仔 皇后大道东248号阳光中心40楼，成立日期2009年7月20日，上市日期2017年7月21日，公司主营业务涉 及涵盖个人防护、康复护理、其他产品三大板块。主营业务收入构成为：个人防护类91.47%，康复护 理类4.75%，其他产品3.77%。 从基金十大重仓股角度 数据显示，华安基金旗下1只基金重仓英科医疗。华安中证全指医疗器械指数发起式A（021469）四季 度增持1200股，持有股数1.88万股，占基金净值比例为2.29%，位居第九大重仓股。根据测算，今日浮 盈赚取约3.76万元。 华安中证全指医疗器械指数发起式A（021469）成立日期2024年11月5日，最新规模1678 ...

Core Viewpoint - The financial performance of Yingke Medical (300677) shows mixed results, with a slight increase in revenue but a significant rise in net profit, indicating potential growth opportunities despite some declines in specific metrics [2]. Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 7.425 billion yuan, an increase of 4.6% year-on-year [2]. - The net profit attributable to shareholders reached 924 million yuan, reflecting a substantial increase of 34.47% year-on-year [2]. - The net profit excluding non-recurring items was 484 million yuan, which represents a decline of 19.32% year-on-year [2]. - In Q3 2025, the company recorded a single-quarter main revenue of 2.511 billion yuan, down 2.9% year-on-year [2]. - The single-quarter net profit attributable to shareholders was 214 million yuan, showing a remarkable increase of 113.04% year-on-year [2]. - The single-quarter net profit excluding non-recurring items was 84.28 million yuan, down 25.87% year-on-year [2]. - The company's debt ratio stands at 53.79%, with investment income of 183 million yuan and financial expenses of 127 million yuan [2]. - The gross profit margin is reported at 23.7% [2]. Stock Performance and Market Sentiment - As of February 6, 2026, the stock closed at 41.36 yuan, with an increase of 1.03% and a turnover rate of 1.6% [1]. - The trading volume was 74,400 hands, with a total transaction value of 309 million yuan [1]. - On February 6, the net inflow of main funds was 3.0677 million yuan, accounting for 0.99% of the total transaction value [1]. - The net inflow of speculative funds was 6.9237 million yuan, representing 2.24% of the total transaction value [1]. - Retail investors experienced a net outflow of 9.9914 million yuan, which is 3.23% of the total transaction value [1]. - Over the last 90 days, six institutions have provided ratings for the stock, with five giving a buy rating and one an increase rating [3].

Group 1 - In the stock market, Yingke Medical experienced a decline of 5.78%, with a current share price of 42.20 yuan, a trading volume of 1.28 billion yuan, a turnover rate of 0.63%, and a total market capitalization of 27.648 billion yuan [1] - Yingke Medical Technology Co., Ltd. is located in Zibo City, Shandong Province, and was established on July 20, 2009, with its listing date on July 21, 2017. The company's main business includes three segments: personal protection (91.47% of revenue), rehabilitation care (4.75%), and other products (3.77%) [1] Group 2 - From the perspective of major fund holdings, Chunhou Fund has one fund heavily invested in Yingke Medical. The Chunhou Times Preferred Mixed A Fund (014235) held 12,000 shares in the fourth quarter, unchanged from the previous period, accounting for 2.84% of the fund's net value, making it the fourth-largest holding. The estimated floating loss today is approximately 31,100 yuan [2] - The Chunhou Times Preferred Mixed A Fund (014235) was established on January 27, 2022, with a latest scale of 14.6472 million yuan. Year-to-date returns are 6.65%, ranking 3,570 out of 8,861 in its category; the one-year return is 39.41%, ranking 3,052 out of 8,126; and since inception, the return is 2.31% [2]

Group 1 - Aishalon is a company focused on the research, development, production, and sales of disposable medical consumables in the rehabilitation care and medical protection sectors [2] - The company emphasizes innovation and development, catering to the professional needs of healthcare workers and patients, and aims for technological innovation and industrial upgrades [2] - Aishalon has expanded its product line to include disinfection, household protection, and emergency protection products, while also providing ODM/OEM services for internationally recognized medical device brands [2] Group 2 - Aishalon operates multiple self-owned factories located in Jiangsu Province (Zhangjiagang and Yancheng), Anhui Province (Xuancheng), Thailand (Ayutthaya), and Morocco, with products exported to over 50 countries and regions including Europe, America, Japan, South Korea, the Middle East, and Africa [2] - Zhonglun Law Firm serves as the issuer's lawyer for Aishalon's public offering and listing project on the Beijing Stock Exchange, providing comprehensive and high-quality legal services throughout the issuance and listing process [2] - The project team includes partners Sun Yu and Qiao Wenjun, along with lawyer Wu Weiwei, and regional partner Cheng Chi, demonstrating a rigorous and professional service approach [2]

Group 1: Market Overview - The A-share market experienced an overall upward trend on January 21, with major indices rising to varying degrees, particularly the electronic sector which saw a surge in limit-up stocks [1][2][5] - The ChiNext Index rose over 1.5%, while the Sci-Tech 50 Index increased by more than 4% during the trading session [2] Group 2: Electronic Sector Performance - The electronic sector led the market with a gain of over 2.8%, with multiple stocks hitting the daily limit-up [5] - Notable stocks included Longxin Technology and Zhongrong Electric, both achieving a limit-up of 20%, while several others like Kexiang Co. and Jiehuate saw increases exceeding 10% [5][6] Group 3: Stock Performance Data - Key stock performance data includes: - Longxin Technology (688047) at 177.72, up 20.00% with a trading volume of 2.075 billion - Zhongrong Electric (301031) at 143.40, up 20.00% with a trading volume of 687 million - Other significant gainers included Haiguang Information (688041) up 12.40% and Dagan Co. (002077) up 10.03% [6] Group 4: Lithium Sector Activity - The lithium mining sector also saw significant gains, with the sector rising over 2% and stocks like Dazhong Mining and Weicheng Mining hitting the daily limit-up [7] - The surge was attributed to a notable increase in domestic lithium carbonate futures, with the main contract rising over 6% [7] Group 5: New Stock Listing - A new stock, Aisheren, debuted on the A-share market with an impressive rise of over 200% during its trading session [9] - Aisheren focuses on the medical health sector, specializing in the development, production, and sales of disposable medical supplies for rehabilitation and medical protection [11] Group 6: Hong Kong Market Highlights - In the Hong Kong market, Skyworth Group saw a significant increase, with its stock price rising over 40% during the trading session [12] - The company announced plans for a distribution and listing of its solar subsidiary, Skyworth Solar, contingent on meeting certain conditions [14][15]

Company and Industry Summary Company: Aisheren (920050) Key Points - **Core Business Focus**: Aisheren specializes in medical dressings, particularly in rehabilitation care and surgical infection control products. The company emphasizes a "core customer" strategy, collaborating closely with major clients to iteratively develop products based on demand and optimize manufacturing processes [1][2]. - **Major Client**: Medline Group has been the largest customer from 2022 to 2024, accounting for over 70% of Aisheren's revenue. This strong client relationship is pivotal for the company's revenue stability and growth [3]. - **Market Trends**: Two primary growth drivers are identified: 1. Enhanced safety and hygiene standards in operating rooms, aligning with practices in Europe and the US. 2. Increased demand for elderly care, opening up opportunities in the consumer market [3]. - **Medline's Global Position**: Medline is recognized as the largest manufacturer and distributor of surgical supplies globally and the fourth largest medical device company. It went public on NASDAQ in December 2025, raising approximately $2.26 billion, which will be invested in local markets and global expansion, as well as supply chain upgrades [3]. - **Capacity Expansion**: Aisheren faced capacity constraints before 2024, but with the commissioning of a factory in Thailand, revenue growth is expected to accelerate. For 2024, revenue and profit growth rates are projected to increase significantly, with year-on-year growth of 20.4% and 20.5% respectively, and for Q3 2025, growth rates are expected to be 42.8% and 27.5% respectively [3]. - **Future Production Plans**: The company plans to continue expanding production capacity in 2026 and 2027, with expected increases of 50% and 30% respectively. New facilities in various locations, including domestic and international sites, will produce customized products, including precision urine bags [3]. - **Investment Outlook**: The low-value consumables market is a necessity for medical institutions, and the global market is steadily expanding. International leading brands are increasing their international business, and contract manufacturers are likely to benefit from shared market expansion opportunities [3].

Core Viewpoint - In recent trading, Yingke Medical experienced a decline of 2.17% with a transaction volume of 517 million yuan, indicating a negative sentiment in the market [1] Financing and Margin Trading - On January 16, Yingke Medical had a financing buy amount of 47.01 million yuan and a financing repayment of 65.46 million yuan, resulting in a net financing outflow of 18.45 million yuan [1] - The total margin trading balance for Yingke Medical as of January 16 is 571 million yuan, with a financing balance of 559 million yuan, representing 2.10% of the circulating market value, which is below the 20th percentile level over the past year [1] - In terms of securities lending, 3,500 shares were repaid and 8,400 shares were sold on January 16, with a selling amount of 348,500 yuan, while the securities lending balance is 11.55 million yuan, exceeding the 80th percentile level over the past year [1] Financial Performance - For the period from January to September 2025, Yingke Medical achieved an operating income of 7.425 billion yuan, reflecting a year-on-year growth of 4.60%, and a net profit attributable to shareholders of 924 million yuan, which is a 34.47% increase year-on-year [2] Shareholder Information - As of September 30, 2025, Yingke Medical had 47,300 shareholders, a decrease of 21.11% from the previous period, while the average number of circulating shares per person increased by 25.65% to 9,832 shares [2] - The top ten circulating shareholders include notable entities such as Huabao Zhongzheng Medical ETF and E Fund Growth Enterprise ETF, with some shareholders reducing their holdings while others increased or newly entered [4] Dividend Distribution - Yingke Medical has distributed a total of 1.903 billion yuan in dividends since its A-share listing, with 245 million yuan distributed over the past three years [3]

Group 1 - The core viewpoint of the article highlights the upcoming IPO of Aisheren, which is set to issue shares at a price of 15.98 yuan, with a total market value of 811 million yuan and a price-to-earnings ratio of 14.99 [2][3] - Aisheren is the largest manufacturer of medical care pads in China, with its main products accounting for 53.41% in rehabilitation care products and 45.76% in surgical infection control products [2][3] - The company has over 20 years of industry experience and has established partnerships with international groups such as Medline, which enhances its future business development prospects [2][3] Group 2 - The company reported a net profit of 691.64 million yuan for the past three years, with a projected growth of 20.36% for 2024 [3] - Revenue figures for the last three years include 574.66 million yuan in 2023 (up 0.19%) and 573.56 million yuan in 2022 [3] - The funds raised from the IPO will be directed towards the construction of the Caple Public Health Medical Supplies Industrial Park [3]

Investment Rating - The investment rating for the company is "Buy" due to its strong market position and growth potential in the medical dressing industry [29]. Core Insights - The company, Jiangsu Aishalen Medical Technology Group Co., Ltd., is a leading player in the domestic medical dressing industry, established in 2015 and headquartered in Suzhou, Jiangsu. It focuses on the research, production, and sales of low-value medical consumables, primarily through ODM/OEM partnerships with internationally recognized medical device brands [3][6]. - The company has shown rapid revenue growth, achieving a revenue of 692 million yuan in 2024, with a three-year CAGR of +9.81%. The net profit attributable to shareholders is projected to be 80.71 million yuan, with a CAGR of +13.37% over the same period [7][23]. - The company is expanding its production capacity to alleviate bottlenecks, driven by increasing orders from overseas markets. The new investment project is expected to significantly enhance production capabilities [9][10]. Summary by Sections Company Overview - Jiangsu Aishalen Medical Technology Group Co., Ltd. ranks among the top ten in medical dressing exports in China from 2021 to 2024 [3][6]. Financial Performance - In 2024, the company is expected to achieve a gross margin of 23.13%, slightly down from 2023, while the net margin is projected to increase to 11.66% [7][23]. Issuance Plan - The company plans to issue 16.92 million shares at a price of 15.98 yuan per share, raising approximately 270 million yuan. The initial issuance will represent 25% of the total shares post-issuance, with a low liquidity ratio of 26.75% [11][12]. Industry Situation - The global market for low-value medical consumables is projected to reach approximately 134.3 billion USD by 2031, with a CAGR of 8.3% from 2024 to 2031. The domestic market is also expected to grow rapidly, driven by healthcare reforms and increased consumer spending [15][16]. Competitive Advantages - The company benefits from scale cost advantages, a strong customer base, and a commitment to product quality, which enhances its competitive position in the market [17]. Purchase Analysis Opinion - The company is recommended for active participation in the upcoming issuance due to its strong market position, high capacity utilization, and low initial valuation [23].

Group 1 - In December 26, 2023, Yingke Medical's stock price fell by 5.04%, closing at 41.28 yuan per share, with a trading volume of 431 million yuan and a turnover rate of 2.20%. The total market capitalization is 27.045 billion yuan. The stock has experienced a consecutive decline over three days, with a cumulative drop of 2.05% during this period [1] - Yingke Medical Technology Co., Ltd. is located in Zibo City, Shandong Province, and was established on July 20, 2009. The company went public on July 21, 2017. Its main business includes three segments: personal protection (91.47% of revenue), rehabilitation care (4.75%), and other products (3.77%) [1] Group 2 - From the perspective of major holdings, one fund under Zhongyou Fund holds a significant position in Yingke Medical. The Zhongyou Strategic Emerging Industries Mixed A Fund (590008) held 1 million shares in the third quarter, accounting for 4.09% of the fund's net value, ranking as the ninth largest holding. The estimated floating loss today is approximately 2.19 million yuan, with a floating loss of 910,000 yuan during the three-day decline [2] - The Zhongyou Strategic Emerging Industries Mixed A Fund (590008) was established on June 12, 2012, with a current scale of 888 million yuan. Year-to-date returns are 30.77%, ranking 3055 out of 8087 in its category; the one-year return is 30.59%, ranking 2900 out of 8074; and since inception, the return is 560% [2]